Ipsen UK
在场
Ipsen UK 的所有者是 Ipsen.
是其中之一......
Ipsen 是一家在股票代码 IPN (FR) 下上市的公司。
Ipsen 在 5 个国家有直接业务。Ipsen 拥有 4家子公司，其中包括 Ipsen Iberica、Ipsen North America 和 Ipsen UK。
他们在：
高管
查看带有其 1 名主要高管的组织结构图
Ipsen UK 搜索最多的简介
高管在Ipsen变化
- Josep CatllàJosep Catllà 将于20248月19作为 Executive Vice President and Chief Corporate Affairs Officer 加入公司 (新闻发布的2024六月7号).
- Stewart Campbell, Executive Vice President, President, North America, 将于 20245月13 退休 (新闻发布的2024五月2号).
- Keira DrianskyKeira Driansky 将于20245月13作为 Executive Vice President and President of North America 加入公司 (新闻发布的2024五月2号).
创建提醒
跟踪 Ipsen UK 的高管变动
药店
Ipsen 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Ipsen UK 的最新新闻稿
- Press Releases - Ipsen UK
- Ipsen shares results from innovative research partnership exploring young people’s attitudes to science - Ipsen UK
- Advanced kidney cancer patients in Scotland become amongst the first in world to access CABOMETYX®▼ (cabozantinib) in combination with OPDIVO® (nivolumab) via NHS Scotland, following SMC acceptance* - Ipsen UK
- New campaign launches to break down taboos around prostate cancer treatment side effects - Ipsen UK
- Ipsen and Mendelian Announce Landmark Partnership to Reshape Rare Disease Diagnosis using Pioneering MendelScan Technology - Ipsen UK
- Advanced kidney cancer patients in Scotland become amongst the first in world to access CABOMETYX®▼ (cabozantinib) in combination with OPDIVO® (nivolumab) via NHS Scotland, following SMC acceptance* - Ipsen UK
- Ipsen shares results from innovative research partnership exploring young people’s attitudes to science - Ipsen UK
- New campaign launches to break down taboos around prostate cancer treatment side effects - Ipsen UK
- Ipsen and Mendelian Announce Landmark Partnership to Reshape Rare Disease Diagnosis using Pioneering MendelScan Technology - Ipsen UK
- Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy - Ipsen UK
- View more press releases Close
